Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 18 October 2024 PM
Telix has announced another tilt at a NASDAQ listing, on the heels of revenue rising above an average of $2 million per day for the third quarter.
The Melbourne-based radiopharma looked to have an IPO in the US to launch on the NASDAQ in May, hoping to raise US$200 million. The following month it pulled the pin at the last minute, having balked at the discounts it would need to offer, saying it didn't need the money.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.